La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Amphastar Pharmaceuticals Gestion
Gestion contrôle des critères 3/4
Le PDG Amphastar Pharmaceuticals' est Jack Zhang, nommé en Jan1996, a un mandat de 28.58 ans. La rémunération annuelle totale est $ 7.72M, composée du salaire de 11.6% et des bonus 88.4%, y compris les actions et options de la société. détient directement 4.8% des actions de la société, d'une valeur de $ 105.11M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 10.8 ans et 5.2 ans.
Informations clés
Jack Zhang
Directeur général
US$7.7m
Rémunération totale
| Pourcentage du salaire du PDG | 11.6% |
| Durée du mandat du directeur général | 28.6yrs |
| Propriété du PDG | 4.8% |
| Durée moyenne d'occupation des postes de direction | 10.8yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 5.2yrs |
Mises à jour récentes de la gestion
Recent updates
Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 05
Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming
Jul 01Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity
May 30Amphastar Pharmaceuticals: Buy When Fear Is Overblown
May 30Reassessing Amphastar Pharmaceuticals
May 15Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Mar 27Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
Mar 04Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today
Jan 04Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E
Dec 20Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet
Dec 03Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth
Sep 18An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued
Sep 03These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Aug 17Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching
Jun 02We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
May 11Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price
Mar 02Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?
Feb 07Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?
Jan 24Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
Nov 02Amphastar: A Pharmaceutical Growth Stock
Oct 06Amphastar wins FDA approval for Epinephrine pre-filled syringes
Aug 16Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond
Aug 08Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 24Amphastar generic vasopressin for increasing blood pressure gets FDA approval
Jul 19We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
Jun 10Amphastar Pharmaceuticals: Stock With An Attractive 6 To 1 Risk-Reward Ratio
May 13I Ran A Stock Scan For Earnings Growth And Amphastar Pharmaceuticals (NASDAQ:AMPH) Passed With Ease
Apr 23Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$167m |
| Mar 31 2024 | n/a | n/a | US$155m |
| Dec 31 2023 | US$8m | US$898k | US$138m |
| Sep 30 2023 | n/a | n/a | US$135m |
| Jun 30 2023 | n/a | n/a | US$102m |
| Mar 31 2023 | n/a | n/a | US$93m |
| Dec 31 2022 | US$7m | US$1m | US$91m |
| Sep 30 2022 | n/a | n/a | US$77m |
| Jun 30 2022 | n/a | n/a | US$91m |
| Mar 31 2022 | n/a | n/a | US$81m |
| Dec 31 2021 | US$7m | US$898k | US$62m |
| Sep 30 2021 | n/a | n/a | US$36m |
| Jun 30 2021 | n/a | n/a | US$10m |
| Mar 31 2021 | n/a | n/a | US$2m |
| Dec 31 2020 | US$6m | US$898k | US$1m |
| Sep 30 2020 | n/a | n/a | US$7m |
| Jun 30 2020 | n/a | n/a | US$4m |
| Mar 31 2020 | n/a | n/a | US$52m |
| Dec 31 2019 | US$6m | US$898k | US$49m |
| Sep 30 2019 | n/a | n/a | US$52m |
| Jun 30 2019 | n/a | n/a | US$53m |
| Mar 31 2019 | n/a | n/a | US$2m |
| Dec 31 2018 | US$6m | US$1m | -US$6m |
| Sep 30 2018 | n/a | n/a | -US$7m |
| Jun 30 2018 | n/a | n/a | -US$9m |
| Mar 31 2018 | n/a | n/a | -US$4m |
| Dec 31 2017 | US$6m | US$880k | US$4m |
Rémunération vs marché: La rémunération totale de Jack ($USD 7.72M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 5.62M ).
Rémunération et revenus: La rémunération de Jack a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Jack Zhang (77 yo)
28.6yrs
Titularisation
US$7,722,768
Compensation
Dr. Yongfeng Zhang, also known as Jack, Ph D., has been President at Amphastar Pharmaceuticals, Inc. since April 10, 2020. He co-founded Amphastar Pharmaceuticals in 1996 and has been its Chief Executive O...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman of the Board | 28.6yrs | US$3.77m | 2.36% $ 53.6m | |
| Co-founder | 28.6yrs | US$7.72m | 4.8% $ 109.4m | |
| CFO, Executive VP of Finance | 10.3yrs | US$2.89m | 0.075% $ 1.7m | |
| Executive VP of Sales | 11.2yrs | US$1.78m | 0.096% $ 2.2m | |
| Senior EVP of Production & EVP of Scientific Affairs | 9.2yrs | US$2.03m | 0.38% $ 8.7m | |
| Senior Vice President of Human Resources & Corporate Communication | 2yrs | pas de données | pas de données | |
| Executive VP of Regulatory Affairs & Clinical Operations | no data | pas de données | pas de données |
10.8yrs
Durée moyenne de l'emploi
65yo
Âge moyen
Gestion expérimentée: L'équipe de direction de AMPH est chevronnée et expérimentée (ancienneté moyenne 10.8 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman of the Board | 28.6yrs | US$3.77m | 2.36% $ 53.6m | |
| Co-founder | 28.6yrs | US$7.72m | 4.8% $ 109.4m | |
| CFO, Executive VP of Finance | 2yrs | US$2.89m | 0.075% $ 1.7m | |
| Executive VP of Sales | 2yrs | US$1.78m | 0.096% $ 2.2m | |
| Lead Independent Director | 22.5yrs | US$362.00k | 0.063% $ 1.4m | |
| Independent Director | 3.2yrs | US$330.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Independent Director | 5.2yrs | US$314.70k | 0.026% $ 600.8k |
5.2yrs
Durée moyenne de l'emploi
65.5yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de AMPH sont considérés comme expérimentés (ancienneté moyenne 5.2 ans).